Suppr超能文献

跨祖先全基因组关联研究确定扩展的CYP2D6基因座是4-羟基他莫昔芬血浆浓度的主要遗传决定因素。

Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations.

作者信息

Khor Chiea Chuen, Winter Stefan, Sutiman Natalia, Mürdter Thomas E, Chen Sylvia, Lim Joanne Siok Liu, Li Zheng, Li Jingmei, Sim Kar Seng, Ganchev Boian, Eccles Diana, Eccles Bryony, Tapper William, Zgheib Nathalie K, Tfayli Arafat, Ng Raymond Chee Hui, Yap Yoon Sim, Lim Elaine, Wong Mabel, Wong Nan Soon, Ang Peter Cher Siang, Dent Rebecca, Tremmel Roman, Klein Kathrin, Schaeffeler Elke, Zhou Yitian, Lauschke Volker M, Eichelbaum Michel, Schwab Matthias, Brauch Hiltrud B, Chowbay Balram, Schroth Werner

机构信息

Division of Human Genetics, Genome Institute of Singapore, Singapore, Singapore.

Singapore Eye Research Institute, Singapore, Singapore.

出版信息

Clin Pharmacol Ther. 2023 Mar;113(3):712-723. doi: 10.1002/cpt.2846. Epub 2023 Jan 31.

Abstract

The therapeutic efficacy of tamoxifen is predominantly mediated by its active metabolites 4-hydroxy-tamoxifen and endoxifen, whose formation is catalyzed by the polymorphic cytochrome P450 2D6 (CYP2D6). Yet, known CYP2D6 polymorphisms only partially determine metabolite concentrations in vivo. We performed the first cross-ancestry genome-wide association study with well-characterized patients of European, Middle-Eastern, and Asian descent (n = 497) to identify genetic factors impacting active and parent metabolite formation. Genome-wide significant variants were functionally evaluated in an independent liver cohort (n = 149) and in silico. Metabolite prediction models were validated in two independent European breast cancer cohorts (n = 287, n = 189). Within a single 1-megabase (Mb) region of chromosome 22q13 encompassing the CYP2D6 gene, 589 variants were significantly associated with tamoxifen metabolite concentrations, particularly endoxifen and metabolic ratio (MR) endoxifen/N-desmethyltamoxifen (minimal P = 5.4E-35 and 2.5E-65, respectively). Previously suggested other loci were not confirmed. Functional analyses revealed 66% of associated, mostly intergenic variants to be significantly correlated with hepatic CYP2D6 activity or expression (ρ = 0.35 to -0.52), and six hotspot regions in the extended 22q13 locus impacting gene regulatory function. Machine learning models based on hotspot variants (n = 12) plus CYP2D6 activity score (AS) increased the explained variability (~ 9%) compared with AS alone, explaining up to 49% (median R ) and 72% of the variability in endoxifen and MR endoxifen/N-desmethyltamoxifen, respectively. Our findings suggest that the extended CYP2D6 locus at 22q13 is the principal genetic determinant of endoxifen plasma concentration. Long-distance haplotypes connecting CYP2D6 with adjacent regulatory sites and nongenetic factors may account for the unexplained portion of variability.

摘要

他莫昔芬的治疗效果主要由其活性代谢产物4-羟基他莫昔芬和内昔芬介导,其形成由多态性细胞色素P450 2D6(CYP2D6)催化。然而,已知的CYP2D6多态性仅部分决定体内代谢产物浓度。我们对欧洲、中东和亚洲血统的特征明确的患者(n = 497)进行了首次跨祖先全基因组关联研究,以确定影响活性和母体代谢产物形成的遗传因素。在一个独立的肝脏队列(n = 149)中进行了全基因组显著变异的功能评估,并进行了计算机模拟。代谢产物预测模型在两个独立的欧洲乳腺癌队列(n = 287,n = 189)中得到验证。在22号染色体q13上包含CYP2D6基因的单个1兆碱基(Mb)区域内,589个变异与他莫昔芬代谢产物浓度显著相关,特别是内昔芬和代谢比(MR)内昔芬/N-去甲基他莫昔芬(最小P分别为5.4E-35和2.5E-65)。之前提出的其他基因座未得到证实。功能分析显示,66%的相关变异(大多为基因间变异)与肝脏CYP2D6活性或表达显著相关(ρ = 0.35至-0.52),并且在扩展的22q13基因座中有六个热点区域影响基因调控功能。与单独的CYP2D6活性评分(AS)相比,基于热点变异(n = 12)加上CYP2D6活性评分的机器学习模型增加了解释的变异性(约9%),分别解释了内昔芬和MR内昔芬/N-去甲基他莫昔芬变异性的49%(中位数R)和72%。我们的研究结果表明,22q13处扩展的CYP2D6基因座是内昔芬血浆浓度的主要遗传决定因素。连接CYP2D6与相邻调控位点的长距离单倍型和非遗传因素可能解释了变异性中无法解释的部分。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验